EWSR1 and neoplasm: Preclinical studies have shown some promise utilizing the CRISPR-Cas9 system, such as the subtotal tumor clearance of subcutaneous Ewing’s sarcoma xenografts in mice treated the CRISPR-Cas9 strategy against EWSR1::FLI1, demonstrated by Mitra et al. [83].